Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Now Covered by TD Cowen

Key Points

• TD Cowen has initiated coverage of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) with a buy rating and a price target of $60.00, indicating potential upside of 58.35% from the stock's last close.
• Recent trading saw Kiniksa shares rise by 3.8%, reaching $37.89, with a market capitalization of $2.81 billion.
• Kiniksa reported a stronger-than-expected quarterly earnings per share of $0.23, exceeding analyst estimates by $0.05, along with revenue of $156.80 million.

Stock analysts at TD Cowen began coverage on shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) in a research report issued on Monday,Briefing.com Automated Import reports. The brokerage set a "buy" rating and a $60.00 price target on the stock. TD Cowen's price objective indicates a potential upside of 58.35% from the stock's previous close.

KNSA has been the subject of several other research reports. Jefferies Financial Group raised their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Wedbush reiterated an "outperform" rating and issued a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Wells Fargo & Company lifted their price objective on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an "overweight" rating in a report on Thursday. Finally, Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Sunday, September 7th. Seven investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $44.29.

Kiniksa Pharmaceuticals International Trading Up 3.8%

Shares of NASDAQ:KNSA traded up $1.40 during trading on Monday, reaching $37.89. 50,771 shares of the company traded hands, compared to its average volume of 646,202. The firm has a market capitalization of $2.81 billion, a price-to-earnings ratio of 947.61 and a beta of 0.20. Kiniksa Pharmaceuticals International has a 52-week low of $17.82 and a 52-week high of $38.13. The business's fifty day moving average is $33.37 and its 200-day moving average is $28.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The company had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Eben Tessari sold 138,614 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $33.20, for a total transaction of $4,601,984.80. Following the transaction, the chief operating officer directly owned 49,915 shares of the company's stock, valued at $1,657,178. The trade was a 73.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Michael R. Megna sold 17,000 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Monday, August 4th. The shares were sold at an average price of $32.35, for a total value of $549,950.00. Following the transaction, the chief accounting officer directly owned 33,041 shares in the company, valued at approximately $1,068,876.35. The trade was a 33.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 561,371 shares of company stock worth $18,825,009. 53.48% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Rubric Capital Management LP lifted its holdings in Kiniksa Pharmaceuticals International by 15.6% in the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company's stock worth $108,184,000 after purchasing an additional 526,567 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Kiniksa Pharmaceuticals International by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company's stock worth $74,606,000 after purchasing an additional 151,604 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Kiniksa Pharmaceuticals International by 22.6% in the 2nd quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company's stock worth $35,067,000 after purchasing an additional 233,668 shares in the last quarter. Qube Research & Technologies Ltd lifted its holdings in Kiniksa Pharmaceuticals International by 277.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company's stock worth $24,581,000 after purchasing an additional 653,236 shares in the last quarter. Finally, Millennium Management LLC increased its stake in Kiniksa Pharmaceuticals International by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company's stock worth $18,815,000 after acquiring an additional 67,452 shares during the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.